BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Due OT, Thakkinstian A, Thavorncharoensap M, Sobhonslidsuk A, Wu O, Phuong NK, Chaikledkaew U. Cost-Utility Analysis of Direct-Acting Antivirals for Treatment of Chronic Hepatitis C Genotype 1 and 6 in Vietnam. Value Health. 2020;23:1180-1190. [PMID: 32940236 DOI: 10.1016/j.jval.2020.03.018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Nguyen Thi Thu P, Ngo Thi Quynh M, Pham Van L, Nguyen Van H, Nguyen Thanh H, Tsai F. Determination of Risk Factors Associated with the Failure of 12 Weeks of Direct-Acting Antiviral Therapy in Patients with Hepatitis C: A Prospective Study. BioMed Research International 2022;2022:1-10. [DOI: 10.1155/2022/6054677] [Reference Citation Analysis]
2 Mukherjee S, Colby D, Ramautarsing R, Popping S, Sriplienchan S, Chinbunchorn T, Phanuphak N, van de Vijver D. Expanding reimbursement of immediate treatment using direct acting antivirals to reduce hepatitis C incidence among HIV positive men who have sex with men in Bangkok, Thailand: A cost effectiveness modelling study. J Virus Erad 2021;7:100042. [PMID: 34141441 DOI: 10.1016/j.jve.2021.100042] [Reference Citation Analysis]
3 Lee HY, Nguyen TT, Park S, Hoang VM, Kim WH. Health Technology Assessment Development in Vietnam: A Qualitative Study of Current Progress, Barriers, Facilitators, and Future Strategies. Int J Environ Res Public Health 2021;18:8846. [PMID: 34444597 DOI: 10.3390/ijerph18168846] [Reference Citation Analysis]
4 Kouroumalis E, Voumvouraki A. Hepatitis C virus: A critical approach to who really needs treatment. World J Hepatol 2022; 14(1): 1-44 [DOI: 10.4254/wjh.v14.i1.1] [Reference Citation Analysis]